3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
OTHER
6
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Conditions
Neoplasms
2
Prostatic Neoplasms
1
Pancreatic cancer, adult
1
Ovarian Neoplasms
1
Opioid-Related Disorders
1
Lymphoma, Follicular
1
Lung Neoplasms
1
Glioblastoma
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
Prednisone
102
enzalutamide
74
Docetaxel
72
Abiraterone Acetate
67
Leuprolide
47
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
45
abiraterone
37
apalutamide
28
Prednisolone
27
bicalutamide
26
Zoledronic Acid
24
pembrolizumab
22
Goserelin
22
radium Ra 223 dichloride
21
darolutamide
21
Triptorelin Pamoate
17
cabazitaxel
15
Androgen Antagonists
15
sipuleucel-T
13
luprolide acetate gel depot
12
Injections
12
Dexamethasone
12
olaparib
11
gallium 68 PSMA-11
10
Mitoxantrone
10
Pluvicto
9
Ipilimumab
9
Dutasteride
9
Cyclophosphamide
9
relugolix
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Prostatic Neoplasms
×
Hematologic Tests
×
Clear all
NCT06717295
2026-01-02
CCANED-CIPHER
Dysplasia Diagnostics Limited
Recruiting
6,000 enrolled